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Objectives: In a rat model of pressure overload hypertrophy, we studied the effects of
intracoronary delivery of mesenchymal stem cells on hemodynamic performance,
exercise capacity, systemic inflammation, and left ventricular reverse remodeling.
Methods: Sprague–Dawley rats underwent aortic banding and were followed up by
echocardiographic scanning. After a decrease in fractional shortening of 25% from
baseline, animals were randomized to intracoronary injection of mesenchymal stem
cells (MSC group; n 5 28) or phosphate-buffered saline solution (control group; n
5 20). Hemodynamic and echocardiographic assessment, swim testing to exhaustion,
and measurement of inflammatory markers were performed before the rats were
humanely killed on postoperative day 7, 14, 21, or 28.
Results: Injection of mesenchymal stem cells improved systolic function in the MSC
group compared with the control group (mean6 standard deviation: maximum dP/dt
30486 230 mmHg/s vs 21696 97 mmHg/s at 21 days and 35736 741 mmHg/s vs
1363 6 322 mm Hg/s at 28 days: P , .001). Time to exhaustion was similarly in-
creased in the MSC group compared with controls (487 6 35 seconds vs 306 6 27
seconds at 28 days; P , .01). Serum levels of interleukins 1 and 6, tumor necrosis
factor–alpha, and brain natriuretic peptide-32 were significantly decreased in animals
treated with mesenchymal stem cells. Stem cell transplantation improved left ventric-
ular fractional shortening at 21 and 28 days. Left ventricular end-systolic and end-
diastolic diameters were also improved at 28 days.
Conclusions: In this model of pressure overload hypertrophy, intracoronary delivery
of mesenchymal stem cells during heart failure was associated with an improvement
in hemodynamic performance, maximal exercise tolerance, systemic inflammation,
and left ventricular reverse remodeling. This study suggests a potential role of this
treatment strategy for the management of hypertrophic heart failure resulting from
pressure overload.
O
ver the past several years, stem or progenitor cell transplantation therapy has
emerged as a promising novel strategy for regenerating lost or damaged
myocardium.1,2 Several cell types have been proposed as potential donors:
skeletal myoblasts, unfractionated or fractionated adult bone marrow stem cells
(hematopoietic, mesenchymal, and endothelial progenitor cells), embryonic stem
cells, and more recently, resident cardiac progenitor cells.2 Controversy exists regard-
ing the possible mechanisms of action responsible for the functional and morphologic
improvements observed with various progenitor cell therapies.2,3 Although stem cell
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BNP-32 5 brain natriuretic peptide
BrdU 5 bromodeoxyuridine
ELISA 5 enzyme-linked immunosorbent assay
GFP 5 green fluorescent protein
LV 5 left ventricular
LVEDD 5 left ventricular end-diastolic diameter
LVEDP 5 left ventricular end-diastolic pressure
LVESD 5 left ventricular end-systolic diameter
LVESP 5 left ventricular end-systolic pressure
MSC 5 mesenchymal stem cell
PBS 5 phosphate-buffered saline solution
differentiation and/or fusion may be responsible, secondary
paracrine mechanisms mediated by transplanted cells may
lead to more important effects such as neovascularization
and angiogenesis, recruitment and expansion of resident car-
diac stem cells, or reduced apoptosis.
The adult bone marrow provides an excellent and practical
source for autologous stem cells. Both hematopoietic
(CD341/CD1331) and mesenchymal (CD342/CD1332)
bone marrow–derived stem cells (MSCs) have demonstrated
efficacy in animal and early human studies of heart failure.4
In an experimental animal model of myocardial infarction,
hematopoietic stem cells have been found to generate de
novo myocardium and improve hemodynamic performance.5
In 1999, Makino and associates6 isolated a cardiomyogenic
cell line from mouse bone marrow–derived mesenchymal
cells that could be induced to differentiate into cardiomyo-
cytes in vitro by the demethylating agent 5-azacytidine.
These cells connected with adjoining cells, formed myo-
tube-like structures, and beat synchronously after 3 weeks
in culture. Studies in animal models of ischemic injury
have shown that transplantation of 5-azacytidine treated
bone marrow–derived MSCs formed cardiac-like muscle
cells and improved global contractile function.7,8 Most at-
tempts to study the potential of stem cell transplantation in
heart failure have been centered on ischemic heart disease.
Nonischemic cardiomyopathy, including cardiac hypertro-
phy resulting from pressure overload, is also a common cause
of end-stage heart failure. Stem cell transplantation may offer
a novel therapeutic option as an adjunct to surgical therapy in
valvular and nonischemic cardiomyopathy. In a rat model of
pressure overload hypertrophy in transition to heart failure,
we studied the hemodynamic and molecular effects of intra-
coronary delivery of bone marrow–derived MSCs. We hy-
pothesized that bone marrow–derived MSC transplantation
would improve ventricular function and exercise capacity
and that these functional benefits would be associated with
an amelioration in profiles of systemic inflammation, volume
overload, and left ventricular (LV) remodeling.The Journal of ThMaterials and Methods
All animals received humane care in compliance with institutional
guidelines and the ‘‘Guide for the Care and Use of Laboratory An-
imals’’ prepared by the Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council.
Experimental Model of Heart Failure
Outbred male Sprague–Dawley rats (200–250 g, Harlan, Indianap-
olis, Ind) were anesthetized, endotracheally intubated, and mechan-
ically ventilated. An upper median sternotomy was performed and
a small titanium clip with an internal diameter of 0.6 mm (Ligaclip
Extra; Ethicon Endo-Surgery, Inc, Cincinnati, Ohio) was applied
across the aorta proximal to the right brachiocephalic artery. All
animals underwent baseline echocardiography 10 weeks after clip
placement. Transthoracic M-mode and 2-dimensional echocardiog-
raphy was performed with a Hewlett-Packard Sonos 5500 Imaging
System (Hewlett-Packard, Palo Alto, Calif) using a 4-MHz trans-
ducer. Images were standardized to short-axis view at the LV mid-
papillary level, and end-systolic diameter (LVESD), end-diastolic
diameter (LVEDD), and fractional shortening were recorded. Start-
ing at 10 weeks after aortic clip placement, echocardiography was
performed weekly. After detection of an absolute decline in frac-
tional shortening of 25% from baseline (relative 50% reduction),
animals were randomized to intracoronary delivery of bone mar-
row–derived MSCs (MSC group, n 5 28), or phosphate-buffered
saline solution (PBS; control group, n 5 20).
Isolation of Bone Marrow–derived MSC and
Culture Technique
Primary cultures of MSCs were obtained from the femurs and tibias
of adult male Sprague–Dawley rats (Taconic Farms, Germantown,
NY) as described previously.9 In brief, rats were humanely killed
with a mixture of 70% carbon dioxide and 30% oxygen. Tibias
and femurs were removed and placed on ice in complete medium
containing minimal essential medium with alpha modification (a-
MEM; Gibco BRL, Life Technologies, Gaithersburg, Md) with
20% fetal calf serum (Atlanta Biologicals, Norcross, Ga), L-gluta-
mine (2 mmol/L), penicillin (100 units/mL), streptomycin (100
mg/mL), and amphotericin B (25 ng/mL; Mediatech, Herndon,
Va). Under sterile conditions, a 21-gauge needle attached to a 10-
mL syringe filled with medium was used to flush out the marrow.
Bone marrow was filtered through a 70-mm nylon mesh and plated
in a 75-cm2 flask (Becton Dickinson, Franklin Lakes, NJ). MSCs
were isolated by their adherence to plastic. About 24 hours after be-
ing plated, nonadherent cells were removed and fresh medium was
added. After the cells had grown to near confluency, they were pas-
saged 2 to 6 times by being detached (0.25% trypsin/1 mmol/L eth-
ylenediaminetetraacetic acid for 5 minutes) and replated at a density
of around 5000 cells/cm2 (high-density conditions). At this point
cells were frozen in vials containing approximately 500,000 cells
per unit. Preliminary studies with reverse-transcriptase polymerase
chain reaction revealed that these cells expressed GATA-4 and
Nkx2.5, which are early cardiac lineage markers (data not shown).
Five days before intracoronary cell delivery in rats, MSCs were
thawed and cultured in 10% a-MEM for 24 hours. The second
day, MSCs were plated and 10% fresh Iscove’s modified Dulbec-
co’s medium was added. In addition, bromodeoxyuridine (BrdU)
was supplemented to the culture medium at a concentration of 5oracic and Cardiovascular Surgery c Volume 135, Number 2 293
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the culture medium at a concentration of 10 mg/mL for 24 hours.
Culture medium was then replaced with fresh 10% Iscove’s modi-
fied Dulbecco’s medium on the fourth day. Finally, on the fifth
day, MSCs were trypsinized and were ready for injection. One hun-
dred fifty microliters of a solution containing 13 106 MSCs in PBS
or PBS alone was mixed with 50 mL of adenosine just before injec-
tion. We chose this particular cell dose on the basis of prior studies
of MSC and myoblast transplantation, which have demonstrated the
safety and efficacy of intracoronary infusion of 1 million cells.10,11
MSC Delivery
Within 48 hours of detection of more than 25% decrease in frac-
tional shortening from baseline and subsequent randomization,
animals were anesthetized and a full median sternotomy was per-
formed. The aorta and main pulmonary artery were encircled
together with 4–0 Prolene polypropylene (Ethicon, Inc, Somerville,
NJ) and a tourniquet was loosely applied. With the use of a 1-mL
syringe attached to a sterile 30-gauge needle, the solution containing
13 106 MSCs in PBS and adenosine, or PBS and adenosine alone,
was injected into the aortic root during brief occlusion of the aorta
and the pulmonary artery (5 seconds). Intracoronary delivery was
confirmed by temporary observation of bradycardia and epicardial
blanching.
MSC Identification and Cell Counting After
Intracoronary Infusion
Additional animals were used to confirm successful delivery of
MSCs. Animals were humanely killed by cardiectomy 2 hours
(n 5 4), 3 days (n 5 4), 7 days (n 5 4), and 21 days (n 5 4) after
intracoronary delivery of MSCs. The hearts were thoroughly
washed with PBS cooled to 4C. After resection of the atria, the ven-
tricles were fixed in 10% formalin for 24 hours. Hearts were embed-
ded in paraffin and cut into slices of 4-mm thickness. Monoclonal
antibodies against BrdU (Zymed BrdU staining kit, San Francisco,
Calif) were used to identify transplanted cells. For each animal at
each time point, 10 separate heart sections were examined under
4003 magnification with an E600 Nikon microscope (Nikon,
Tokyo, Japan). The number of BrdU-labeled cells per section was
quantified by the BIOQUANT Life Science Core Analysis System
(Bioquant Image Analysis Corporation, Nashville, Tenn).
Echocardiographic Assessment and Hemodynamic
Measurement
Within the treatment groups, animals were randomly assigned to be
humanely killed on postoperative day 7, 14, 21, or 28 (5 animals at
each time interval in the control group and 7 animals at each time
interval in theMSC group). Animals were anesthetized and echocar-
diographic assessment was performed. Images were standardized to
short-axis view at the LV midpapillary level, and fractional shorten-
ing, LVESD, LVEDD, and LV free wall diameter were recorded.
Subsequently, a full median sternotomy was performed. A 21-gauge
intravenous catheter connected to a Digi-Med System Integrator
model 200 (Micro-Med, Louisville, Ky) was advanced from the
ventricular apex into the LV cavity. Heart rate, LV end-systolic pres-
sure (LVESP), LV end-diastolic pressure (LVEDP), time constant
of isovolumetric pressure decay (tau), rate of rise of LV pressure
(dP/dtmax), and rate of fall of LV pressure (dP/dtmin) were recorded.294 The Journal of Thoracic and Cardiovascular Surgery c FebFive milliliters of blood was then withdrawn for enzyme-linked
immunosorbent assay (ELISA) analysis. Animals were humanely
killed by cardiectomy.
Exercise Testing
All animals underwent swim testing to exhaustion 1 day before
being killed. As described by Musch and colleagues,12 this protocol
has been shown to cause a rat to use 65% to 70% of its maximum
oxygen consumption. Exhaustion was defined as the time at which
the animal was no longer able to consistently keep its head above the
water level. Investigators remained blinded to the treatment groups
throughout the experiments to avoid bias.
ELISA Analysis
Blood samples were allowed to clot for 2 hours at room temperature
before centrifugation for 20 minutes at approximately 2000g. The
serum was removed, an aliquot was obtained, and it was stored at
270C. Cytokines and cachectins were quantified with the follow-
ing ELISA kits: Quantikine Rat IL-1 beta (R&D Systems, Minneap-
olis, Minn), Quantikine Rat IL-6, Quantikine Rat TNF-alpha, and
Rat BNP-32 Immunoassay Kit (Peninsula Laboratories, San Carlos,
Calif). Optical density was obtained within 30 minutes by an MRX
Dynatech Laboratories microplate reader (Dynatech Laboratories,
Inc, Foster City, Calif) and Revelation version 1.01 software (Rev-
elation Software, London, United Kingdom). Readings were taken
at 540 nm and subtracted from readings at 450 nm to correct for op-
tical imperfections in the plates. Duplicate readings for each sample,
control, and standard were averaged, subtracting out the average
zero standard optical density. A standard curve was constructed
by plotting the mean absorbance for each standard in the y-axis
against the concentration on the x-axis with a best fit curve drawn
through the points on the graph.
Statistical Analysis
All data are presented as mean 6 standard deviation. Between-
group differences in frequency data were analyzed by the Fisher
exact test. Differences in continuous variables were analyzed by in-
dependent t tests. Analysis of variance with least significant differ-
ence procedure was used. After analysis of variance, a Bonferroni
post hoc analysis was used for adjustment for multiple comparisons.
The SAS v8.1 software (SAS Institute, Inc, Cary, NC) was used for
statistical analysis.
Results
Development of Heart Failure
A decline of 25% of fractional shortening after aortic banding
compared with baseline was detected between 175 and
237 days after clip placement for all animals (mean 6 SD:
2036 15 days). There were no statistical differences between
treatment groups (202 6 14 days vs 205 6 18 days for the
MSC and control groups, respectively; P 5 .55). Fractional
shortening was also similar between animals in the MSC
and control groups at baseline echocardiographic assessment
(51.2% 6 1.7% vs 51.0% 6 2.2%: P 5 .71) and treatment
randomization (26.5% 6 1.7% vs 26.0% 6 2.1%; P 5 .41).
We observed a combined 30% mortality rate during aortic
clip placement and development of heart failure.ruary 2008
Molina et al Surgery for Acquired Cardiovascular DiseaseTABLE 1. Hemodynamic parameters at 7, 14, 21, and 28 days after treatment
7 Days 14 Days 21 Days 28 Days
Control MSC Control MSC Control MSC Control MSC
HR (beats/min) 326 6 32 316 6 41 324 6 40 311 6 32 323 6 40 315 6 39 298 6 33 286 6 29
LVESP (mm Hg) 112 6 16 114 6 15 105 6 12 111 6 13 99 6 10 115 6 11* 91 6 9 122 6 14*
LVEDP (mm Hg) 16 6 4 15 6 3 17 6 5 14 6 4 19 6 5 12 6 4 22 6 4 11 6 3*
Tau (ms) 26 6 5 25 6 4 28 6 4 25 6 3 29 6 5 23 6 3 31 6 3 22 6 2*
MSC, Mesenchymal stem cell; HR, heart rate; LVESP, left ventricular end-systolic pressure; LVEDP; left ventricular end-diastolic pressure; tau, the time
constant of isovolumetric pressure decay. *P , .05 for comparison of control group versus MSC group.A
CDAdditionally, 4 animals died after treatment (3 in the control
group and 1 in the MSC group).
MSC Identification and Cell Counting After
Intracoronary Infusion
Figure E1 shows a representative section of LV myocardium
2 hours after intracoronary delivery of MSCs. Numerous
BrdU-labeled MSCs (brown nuclei) are seen by light micros-
copy (4003). Some of these cells are visualized within or
around capillary vessels. Blue-stained nuclei correspond to
cardiomyocytes and endothelial cells. Figure E2 shows a
section of myocardium 21 days after MSC transplantation.
Although the intensity of the brown staining has decreased,
several BrdU-positive nuclei can be distinguished among
blue-stained nuclei of native cardiomyocytes. We found the
following average number (6SD) of BrdU-positive cells
per high-power field at each time interval: 205 6 74 cells
at 2 hours, 195 6 44 cells at 3 days, 180 6 64 cells at
7 days, and 38 6 23 cells at 21 days.
Hemodynamic Assessment
Hemodynamic parameters were measured at similar heart
rates for both groups (Table 1). The control group showed
a decline in LVESP and a rise in LVEDP with progression
of heart failure. The MSC group, however, demonstrated sig-
nificantly increased LVESP and reduced LVEDP compared
with the control group at 28 days after treatment. The time
constant of isovolumetric pressure decay (tau) was found to
be prolonged in controls and decreased in animals receiving
MSCs at 28 days. As shown in Figure 1, animals receiving
MSCs revealed stabilization of LV systolic function (dP/
dtmax) after treatment. However, control animals revealed
a steady decline of systolic function as heart failure pro-
gressed. The differences were significant at 21 days and 28
days. Similar findings were demonstrated with diastolic
relaxation (dP/dtmin), as shown in Figure E3.
Exercise Test
Both groups of animals were able to swim for longer periods
of time as they recovered from the median sternotomy proce-
dure at day 0. However, animals receiving MSCs demon-
strated improved exercise capacity at all time intervals inThe Journal of Thorcomparison with the control group (Figure 2). These differ-
ences were statistically significant at 21 and 28 days.
Systemic Inflammation and Volume Overload
Serum levels of systemic inflammatory markers are shown
in Table 2. Levels of interleukins 1 and 6 and tumor necrosis
factor–a were decreased in MSC-treated animals at every
time interval in comparison with the control group, which
demonstrated increasing levels as heart failure progressed.
These differences were significant at 21 and 28 days. Levels
of brain natriuretic peptide–32 (BNP-32), also shown in
Table 2, were remarkably decreased in the cell treatment
group at 21 and 28 days compared with the control group.
Echocardiographic Assessment
Control animals revealed a steady decline of fractional short-
ening as heart failure progressed. The MSC group, however,
demonstrated stabilization of fractional shortening and
a slight improvement at 28 days. These differences were sta-
tistically significant at 21 and 28 days (Figure 3). Control an-
imals showed a gradual increase of LVESD as heart failure
progressed. The MSC group revealed stabilization of LV di-
latation and a slight reduction of this diameter at 28 days.
These differences were again statistically significant at 21
and 28 days (Figure 4). LVEDD was found to increase in
control animals with progression of heart failure. The cell
transplantation group, however, demonstrated early stabiliza-
tion and subsequent improvement (Figure 5). Control ani-
mals showed a decline of free wall diameter as heart failure
progressed. Animals receiving cells demonstrated less reduc-
tion of this diameter. These differences were statistically
significant at 21 days only (Figure E4).
Discussion
The use of stem cell populations to improve the structure and
function of the damaged heart is an exciting and controversial
area, generating great debate over the efficacy and mecha-
nism of action of injected cells.1,2 Most attempts have been
centered in animal models of ischemic heart disease. To
date, only two studies have examined the potential beneficial
effects of bone marrow–derived stem cell transplantation in
nonischemic animal models. Agbulut and coworkers13acic and Cardiovascular Surgery c Volume 135, Number 2 295
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bone marrow cells in a murine model of doxorubicin-induced
dilated cardiomyopathy. However, the authors questioned
the potential functional efficacy of this finding because of
the very low number of transdifferentiated cells they ob-
served. Recently, Nagaya and associates14 reported improved
cardiac function after MSC transplantation in a rat model of
myocarditis leading to dilated cardiomyopathy. To our
knowledge, no studies have evaluated the efficacy of stem
cell transplantation therapy in an animal model of pressure
overload–induced heart failure.
The degree of functional improvement observed in the
present study after bone marrow–derived MSC transplanta-
tion is remarkable. Control animals showed a continuous
decline in systolic and diastolic function as heart failure
progressed after treatment with PBS. Animals in the MSC
group, however, demonstrated stabilization of LV contractil-
ity and improved ventricular relaxation after cell transplanta-
tion therapy. These findings were most remarkable at 21 and
28 days after treatment. Similarly, we report a significant
improvement in exercise capacity in the MSC group com-
pared with controls. As the median sternotomy wound pro-
gressively healed, both animal groups showed better
exercise tolerance. This improvement was also observed in
the control group, despite a progressive decline in systolic
and diastolic function. However, animals that received
MSCs demonstrated significantly improved exercise perfor-
mance compared with controls at later intervals. Although
an improvement in exercise capacity after cell transplantation
therapy in heart failure is not a novel finding,15 we believe
this is a remarkable observation in this animal model in tran-
sition to advanced heart failure.
It has been demonstrated that progression of heart failure is
associated with upregulation of tumor necrosis factor–a, inter-
Figure 1. Left ventricular maximal dP/dt at each time interval.
*P < .05 and **P < .001 MSC versus control group. MSC, Mesen-
chymal stem cell.296 The Journal of Thoracic and Cardiovascular Surgery c Febleukin 1, and interleukin 6 plasma levels. These mediators ac-
tivate several key pathways in the cell that enhance matrix
remodeling, promote apoptosis and depress cardiac contractil-
ity.16 In this study, we report a remarkable decline in tumor ne-
crosis factor–a, interleukin 1, and interleukin 6 serum levels in
the cell treatment group at 21 and 28 days. These findings sup-
port the hypothesis thatMSC treatment ameliorates the inflam-
matory response that is associated with progression of heart
failure. However, this study was not designed to provide any
specific mechanistic insight to reveal the biological effects of
MSCs on these different pathways.
BNP-32 is a cardiac neurohormone specifically secreted
by ventricular myocytes in response to ventricular volume ex-
pansion, pressure overload, and increased wall tension. A de-
cline in BNP-32 serum levels is a useful indicator of response
Figure 2. Maximal exercise tolerance at each time interval.
*P< .01 MSC versus control group.MSC,Mesenchymal stem cell.
Figure 3. Changes in fractional shortening (FS) from day 0 at each
time interval. *P< .01 MSC versus control group.MSC,Mesenchy-
mal stem cell.ruary 2008
Molina et al Surgery for Acquired Cardiovascular DiseaseTABLE 2. Serum levels (pg/mL) of inflammatory markers and BNP-32 at 7, 14, 21, and 28 days after treatment
7 Days 14 Days
Control MSC % D Control MSC % D
IL-1 34.22 6 1.76 33.37 6 1.49 22.5 36.12 6 1.51 34.46 6 0.58 24.6
IL-6 179.84 6 15.7 173.21 6 6.2 23.7 190.94 6 8.9 179.73 6 4.7 25.9
TNF-a 15.88 6 2.55 15.04 6 1.83 25.3 17.76 6 2.20 16.24 6 1.33 28.6
BNP-32 23.92 6 6.10 23.11 6 5.30 23.4 28.08 6 3.95 25.73 6 3.98 28.4
BNP, Brain natriuretic peptide;MSC,mesenchymal stem cell; IL, interleukin; TNF, tumor necrosis factor. *P, .05 for comparison of control group versus MSC
group.A
CDto medical therapy in patients with end-stage heart failure.17
The remarkable decline in serum levels of BNP-32 that we
observed in the MSC treatment group demonstrates an ame-
lioration of the volume overload state associated with
advanced heart failure.
In the present study, we also report echocardiographic
signs of reverse remodeling in animals receiving MSCs, such
as improved fractional shortening, decreased LVESD and
LVEDD, and improvement of LV free wall diameter.
Although several studies have shown beneficial effects of cell
transplantation therapy on fractional shortening and LV diame-
ters in animal models of heart failure,10,14,18,19 echocardio-
graphic signs of reverse remodeling have not been previously
reported in this model of pressure overload hypertrophy. The
moderate improvementweobserved on these echocardiographic
parameters was seen after a single dose of 1 million MSCs. It is
unknown whether higher doses or repeated doses of MSCs
would lead to a significantlybetter improvement.Dose–response
testing studies with longer follow-up intervals are needed.
The improvement in hemodynamic performance and ex-
ercise capacity we observed, and the echocardiographic
signs of reverse remodeling associated with these beneficial
functional effects, correlated histologically with the pres-
Figure 4. Changes in left ventricular end-systolic diameter
(LVESD) from day 0 at each time interval. *P< .01 MSC versus con-
trol group. MSC, Mesenchymal stem cell.The Journal of Thoence of BrdU-stained cells at early and late time intervals.
A significant percentage of the number of BrdU-stained
cells visualized immediately after delivery (2 hours) were
present at 3 days (95%) and 7 days (88%). The percentage
of BrdU-positive cells observed at 21 days was still signif-
icant (18%). Whether these cells represent MSCs, transdif-
ferentiated cardiomyocytes, or fused cells is unknown.
However, these findings demonstrate that a significant num-
ber of cells visualized immediately after intracoronary
delivery are able to survive and may play a significant bio-
logical role 21 days later, when most of the functional and
molecular beneficial findings we reported are manifested.
It is reasonable to speculate that some of these biological
effects may be mediated by paracrine mechanisms. A hy-
pothesis that is growing in interest is that MSCs may be
able to ameliorate the local inflammatory response, promote
angiogenesis, improve the myocardial apoptotic profile, and
promote reverse remodeling through the action of growth
factors.4,20 Currently, we are investigating the LV tissue
levels of key growth factors such as vascular endothelial
growth factor, insulin-like growth factor, hepatocyte growth
factor, and platelet-derivated growth factor after cell trans-
plantation in this model.
Figure 5. Changes in left ventricular end-diastolic diameter
(LVEDD) from day 0 at each time interval. *P < .01 MSC versus
control group. MSC, Mesenchymal stem cell.racic and Cardiovascular Surgery c Volume 135, Number 2 297
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Control MSC % D Control MSC % D
37.15 6 0.76 33.86 6 0.63* 28.6 41.08 6 1.36 32.40 6 1.17* 221.1
205.80 6 5.7 171.34 6 2.0* 216.8 228.58 6 8.2 167.83 6 6.0* 226.6
19.38 6 0.61 15.59 6 0.67* 219.6 26.10 6 1.99 14.64 6 1.20* 243.9
30.08 6 0.26 21.11 6 1.80* 229.8 36.85 6 3.24 19.84 6 3.08* 246.2
TABLE 2. ContinuedTo our knowledge, this study demonstrates for the first
time beneficial effects of MSC transplantation therapy in
a model of pressure overload hypertrophy. On the basis of
these results, we speculate that patients with aortic stenosis
or hypertension in transition to heart failure may potentially
benefit from bone-derived MSC transplantation therapy
(combined with aortic valve replacement, for example).
However, we should be very cautious about the clinical im-
plications of this study. Additional small animal studies
should confirm these results. Studies in large animal models
should also be conducted before entering into the clinical
arena. Many important questions need to be answered first:
Are MSCs the optimal cell population? What is the best
method of delivery? What is the most effective dose? Is a sin-
gle dose effective enough or are multiple doses required to
achieve a sustained response? Do cells need to be treated
with 5-azacytidine or other inductor of differentiation? Are
these inductors safe? Do MSCs have significant side effects?
Do bone marrow–derived MSCs from older patients have the
same therapeutic potential as cells from younger patients?
What is the role of combined therapies?
In conclusion, intracoronary delivery of MSCs during
heart failure in this model of pressure overload hypertrophy
improved hemodynamic performance and maximal exercise
tolerance. MSC transplantation was also associated with im-
provement in markers of systemic inflammation, volume
overload, and echocardiographic signs of LV reverse remod-
eling. These effects were most remarkable at 21 and 28 days
after injection. This study suggests a potential role of this
treatment strategy for the management of hypertrophic heart
failure resulting from pressure overload.
We express sincere gratitude to Dr S. Azizi, Dr B. Krynska, and
B. Augelli (Neurology Department, Temple University School of
Medicine) for providing mesenchymal stem cells and continuous
technical support throughout this study.
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Dr Y. Joseph Woo (Philadelphia, Pa).You should be congratulated
for a fantastic study, particularly with the technical aspects that you
showed and also the creative water bath assay. You answered a lot of
the potential questions that the audience would have with in your
last two slides.
Your study is very good at showing the effects of your therapy.
To take your study to the next level, you should show some mech-
anistic components. The investigators who are doing a lot of the
stem cell transplantation work are thinking that there is not much
cross-linking of the cells and probably not a tremendous contractile
contribution from stem cell transplantation, but rather some sort of
biofactory effect. You did measure a multitude of different parame-
ters. Can you comment on some of the other things that you may be
in the process of measuring that would perhaps better elucidate the
mechanism in effect here?
Dr Molina. Thank you, Dr Woo, for your comments and ques-
tions. Regarding the mechanisms of action of bone marrow–derived
MSCs, I think that is one of the fundamental questions in this area of
research, as you mentioned. The contribution of MSCs to the im-
provement in contractile function of these hearts is probably mild.
Contractile function is improved in treated animals in comparison
with the control group at 21 and 28 days after therapy, but if we com-
pare treated animals with baseline contractility before cell transplan-
tation, it is probably similar. We think that both systolic and diastolic
function became stable after treatment. Treatment with bone mar-
row–derived MSCs, at least in this study, avoided the deterioration
in contractility that occurs with progression of heart failure. Whether
the cells really differentiate into cardiomyocytes is still unknown.
We are still running studies to identify these cells at later intervals,
and we are planning to do it with confocal microscopy. However,
there are other findings that I did not present that are also significant
in terms of alternative potential mechanisms of action. We have
measured tissue growth factors in these hearts, and several ofThe Journal of Thothem are significantly increased in the cell treatment group: for
example, insulin-like growth factor, hepatocyte growth factor, and
platelet-derived growth factor. We think that the paracrine effects
that these cells exert on native cardiomyocytes might play a very
significant role in terms of the mechanisms of action.
Dr Beat H. Walpoth (Geneva, Switzerland). Although you
stated improvements in remodeling, function, and anti-inflamma-
tion, so far as I have seen, you have only shown one slide with
a few labeled cells at a very early time point after injection. Did
you find any surviving cells at 28 days and did you try to quantify
them? Additionally, differentiation and characterization of the in-
jected cells would be helpful to support your hemodynamic results.
Dr Molina. Thank you for your question. These cells were
marked not only with BrdU, as I showed in two slides, but also
with green fluorescent protein (GFP). Both of these markers tend
to disappear with cellular division. By Western blot analysis we
were able to find cells positive for GFP only up to 14 days after
cell injection. We did not find any GFP after that time interval. As
I mentioned before, we are still in the process of obtaining images
with confocal microscopy at later time intervals, which represents
a challenging task.
In our next studies we are planning to use GFP with a lentiviral
GFP adenovirus transfection, which is a much more stable transfec-
tion and is going to allow us to trace these cells for longer periods of
time.
Dr Mark J. Krasna (Baltimore, Md). Dr Molina, I have one
quick question. Technically, you were able to do two sternotomies
and a swim time. Did any of these rats die? In the manuscript it
appears that they all survived.
Dr Molina. Not all of them survived. In the first operation, aortic
clip placement, there was a survival of about 70%. About 15% of the
animals died during or right after the operation, usually of respira-
tory complications, and another 15% usually died during the
follow-up period as heart failure developed.racic and Cardiovascular Surgery c Volume 135, Number 2 299
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CDFigure E1. Section of left ventricular myocardium 2 hours after
intracoronary delivery of mesenchymal stem cells (4003).
Figure E3. Left ventricular maximal negative dP/dt at each time
interval. *P < .01 MSC versus control group. MSC, Mesenchymal
stem cell.299.e1 The Journal of Thoracic and Cardiovascular Surgery c FFigure E2. Section of left ventricular myocardium 21 days after
intracoronary delivery of mesenchymal stem cells (4003).
Figure E4. Changes in free wall diameter (FWD) from day 0 at each
time interval. *P< .01 MSC versus control group.MSC,Mesenchy-
mal stem cell.ebruary 2008
